Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instabilit...
F. Flauto, G. Neola, Alessia Cimadamore et al.· The Oncologist· 0 citations
Abstract Background Cardiovascular disease is a major source of morbidity in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy (ADT)-based treatment. Although cardiovascular risk assessment is increasingly recommended before treatment initiation, its integration i...
T. Alom, A. Kutty, G. Neola et al.· The Oncologist· 0 citations
AI models show moderate-to-good discrimination for ICI response and OS prognosis in BLCA, but evidence is constrained by reliance on a single trial cohort (IMvigor210) and training cohort (TCGA-BLCA), with internal and external OS validation each corroborated by only one study, limiting generalisability.
R. Das, B. Gonsalves, V. Ravindran et al.· The Oncologist· 0 citations
Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice and longer follow-up is needed to establish how these reductions affect overall efficacy.
H. Abdallah, Y. Owoseni, B. Baraka et al.· ESMO real world data and dig...· 0 citations
An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.
D. Khanna, T. Dey, E. Blanchard-Cavagis et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.